Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01888965 · ClinicalTrials.gov registry record · Phase 2
Maintenance Dovitinib for Colorectal and Pancreas Cancer
A Phase 2 study, sponsored by Georgetown University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT01888965 is a Phase 2 study that was terminated before completion, run by Georgetown University. The registered enrollment target is 9 participants.
The verdict
NCT01888965, a Phase 2 study, was terminated before completion, sponsored by Georgetown University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study is for patients with stage 4 colon cancer who have had initial chemotherapy or had surgery to remove metastases and patients with pancreas cancer, which has been surgically removed and are receiving adjuvant chemotherapy or is locally advanced and have already received chemotherapy and radiation. The purpose of this study is to determine the effects of oral dovitinib in patients with advanced stage colorectal and pancreas. Effects include biomarker changes, progression-free survival and safety. Dovitinib will be taken by mouth for 5 days out of every week for up to 2 years.
Interventions
- DRUG Dovitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2013-10 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01888965
The ClinicalTrials.gov registry entry for NCT01888965 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dovitinib is the first listed.
NCT01888965 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01888965 about?
NCT01888965 is a clinical study titled "Maintenance Dovitinib for Colorectal and Pancreas Cancer". This study is for patients with stage 4 colon cancer who have had initial chemotherapy or had surgery to remove metastases and patients with pancreas cancer, which has been surgically removed and are receiving adjuvant chemotherapy or is locally advanced and have already received chemotherapy and ra...
What is the current status of trial NCT01888965?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2013-10. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01888965?
The interventions under investigation include: Dovitinib (DRUG).
Who is sponsoring clinical trial NCT01888965?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.